LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

LENZ Therapeutics submitted an NDA to the FDA for LNZ100, an aceclidine-based eye drop for treating presbyopia, supported by positive Phase 3 CLARITY study results.